Metabolic Brain Disease

, Volume 23, Issue 1, pp 51–69

Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease

ORIGINAL PAPER

DOI: 10.1007/s11011-007-9080-3

Cite this article as:
Watanabe, Y., Kato, H. & Araki, T. Metab Brain Dis (2008) 23: 51. doi:10.1007/s11011-007-9080-3

Abstract

We examined the effects of 7-nitroindazole on the dopaminergic system in mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. The mice received four intraperitoneal injections of MPTP (20 mg/kg) at 2 h-intervals. Administration of 7-nitroindazole showed dose-dependent neuroprotective effects against striatal dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) depletion 7 days after MPTP treatment. Behavioral testing showed that MPTP-treated mice exhibited motor deficits in the catalepsy test after 7 days, but 7-nitroindazole prevented the appearance of motor abnormalities in this test. The MPTP-treated mice exhibited the loss of tyrosine hydroxylase-containing dopaminergic neurons in mice after 1, 3 and 7 days, but 7-nitroindazole-treated mice showed a protective effect. GFAP (glial fibrillary acidic protein)-positive astrocytes were accumulated in the striatum 3 and 7 days and in the substantia nigra 1, 3 and 7 days after MPTP treatment. In contrast, 7-nitroindazole prevented a significant increase in the number of GFAP-positive astrocytes in the striatum and substantia nigra after MPTP treatment. The reactive astrocytes in the striatum and substantia nigra after MPTP treatment increased the production of S100β protein, which is thought to promote neuronal damage, but 7-nitoindazole suppressed the expression of S100 β protein. Activation of microglia, with an increase in staining intensity and morphological changes, was observed in the striatum and substantia nigra 1 and 3 days after MPTP treatment, but 7-nitroindazole prevented a significant increase in the number of isolectin B4 positive microglia in the striatum and substantia nigra. On the other hand, nestin- immunoreactive cells were increased significantly in the striatum 3 and 7 days after MPTP treatment. 7-Nitroindazole treatment facilitated nestin expression in the striatum 7 days after MPTP treatment. Thus, nNOS inhibitor 7-nitroindazole protected dopaminergic neurons against MPTP neurotoxicity in mice and ameliorated neurological deficits. The results suggest that the neuroprotection is mediated though the modulation of glial activation, including the inhibition of S100β synthesis and the prevention of microglial activation. These results suggest the therapeutic strategy targeted to glial modulation with 7-nitoindazole offers a great potential for the development of new neuroprotective therapies for Parkinson’s disease.

Keywords

7-NitroindazoleImmunohistochemistryWestern blot analysisNeuronal nitric oxide synthaseDopaminergic systemNeurogenesisMice

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Neurobiology and Therapeutics, Graduate School and Faculty of Pharmaceutical SciencesThe University of TokushimaTokushimaJapan
  2. 2.Department of Neurology, Organized Center of Clinical MedicineInternational University of Health and WelfareTochigiJapan
  3. 3.Department of Neurobiology and Therapeutics, Graduate School and Faculty of Pharmaceutical SciencesThe University of TokushimaTokushimaJapan